Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

The depressed company could use Mylotarg as a stepping stone in AML.

After Niagara the company faces three pivotal catalysts; none is a slam-dunk.

The group eyes a broader use than Immunocore’s Kimmtrak.

An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.